Get the Stockscreener App
41.37
5.04%
-2.195
Pre-market:
42.05
0.685
+1.66%
Structure Therapeutics Inc Adr stock is traded at $41.37, with a volume of 1.41M.
It is down -5.04% in the last 24 hours and down -9.92% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$43.56
Open:
$43.31
24h Volume:
1.41M
Relative Volume:
1.52
Market Cap:
$2.94B
Revenue:
-
Net Income/Loss:
$-141.43M
P/E Ratio:
-16.83
EPS:
-2.4581
Net Cash Flow:
$-226.41M
1W Performance:
-11.04%
1M Performance:
-9.92%
6M Performance:
+39.89%
1Y Performance:
+59.65%
1-Day Range:
$40.68
$44.00
1-Week Range:
$40.68
$48.03
52-Week Range:
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
41.37 | 3.10B | 0 | -141.43M | -226.41M | -2.4581 |
VRTX
Vertex Pharmaceuticals Inc
|
423.24 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.19 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Structure Therapeutics Reports Weight Loss Success in Obesity Drug Trial - HarianBasis.co
Structure Therapeutics (GPCR) Leerink Global Healthcare Conference 2025 Summary - Quartr
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions - The Manila Times
Five obesity and diabetes studies from Structure Therapeutics head to ADA - Stock Titan
Peregrine Capital Management LLC Buys Shares of 84,324 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
[ARS] Structure Therapeutics Inc. SEC Filing - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) details 2026 virtual shareholder meeting - Stock Titan
Structure Therapeutics (GPCR) COO & GC Matthew Lang files initial Form 3 - Stock Titan
Structure Therapeutics (GPCR) Proxy filing Summary - Quartr
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Discipline and Rules-Based Execution in GPCR Response - Stock Traders Daily
Is Structure Therapeutics (GPCR) Building a Legal-Led Edge in Its Obesity and Metabolic Pipeline Strategy? - Sahm
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
FMR LLC funds trim 17,452 Structure Therapeutics (GPCR) ADS holdings - Stock Titan
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill - TradingView
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results? - TradingView
Structure Therapeutics Appoints Matthew Lang as COO and General Counsel to Advance Obesity Drug Pipeline - Minichart
Structure Therapeutics stock rating maintained at Outperform by Leerink - Investing.com
Structure Therapeutics Appoints Matthew Lang as Chief Operating Officer - TipRanks
Structure Therapeutics (NASDAQ: GPCR) appoints Matthew Lang as COO and General Counsel - Stock Titan
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel - The Manila Times
Structure Therapeutics names Matthew Lang as COO and counsel - Investing.com
Metsera legal chief joins Structure as COO ahead of Phase 3 - Stock Titan
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval? - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
SG Americas Securities LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Behavioral Patterns of GPCR and Institutional Flows - Stock Traders Daily
Why Structure Therapeutics Stock Is Suddenly Sinking - TipRanks
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Why Structure Therapeutics Stock Suddenly Took Off Today - TipRanks
Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Structure Therapeutics Stock Is Suddenly Surging - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8%What's Next? - MarketBeat
LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill? - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail
Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Sahm
Structure Therapeutics Stock Jumps on Obesity Drug Buzz - TipRanks
Structure Therapeutics Shares Surge on Obesity Drug Breakthrough - TipRanks
Structure Therapeutics (GPCR) Is Down 5.5% After Strong Oral GLP-1 Phase 2 DataWhat's Changed - Sahm
Structure Therapeutics (NASDAQ:GPCR) Stock Rating Lowered by Wall Street Zen - MarketBeat
Structure Therapeutics Obesity Trial Success Puts Valuation Gap In Focus - Sahm
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at Wolfe Research - MarketBeat
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Wolfe Research initiates Structure Therapeutics stock rating at Peerperform By Investing.com - Investing.com India
Wolfe Research initiates Structure Therapeutics stock rating at Peerperform - Investing.com
GPCR SEC FilingsStructure Therapeutics Inc ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):